Synthesis and antihyperlipidemic activity of some novel condensed 2-chloroalkyl-4-chloro/hydroxy-5,6-disubstituted Pyrimidines

被引:0
作者
Kathiravan, Matthu K.
Shishoo, Chamanlal J.
Kumar, Krishnan Girish
Roy, Saroj Kumar
Mahadik, Kakasheb R.
Kadam, Shivajirao S.
Jain, Kishor S.
机构
[1] Sinhgad Coll Pharm, Pune 411041, Maharashtra, India
[2] Poona Coll Pharm, Pune 411038, Maharashtra, India
[3] LM Coll Pharm, Ahmadabad 380009, Gujarat, India
来源
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH | 2007年 / 57卷 / 09期
关键词
antiltyperlipidemic drugs; cholesterol; hyperlipidemia; thienopyrimidines; antihyperlipidemic activity; synthesis; Triglycerides; mriton;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Synthesis and antihyperlipidemic activity of a series of novel condensed 2-chloroalkyl-4-chloro/hydroxy-5,6-di-substituted pyrimidines are described. The design of these compounds is based on the earlier QSAR study on the antibyperlipidemic 2-substituted methylthienopyrimidin-4-ones. The newly synthesized condensed 4-chloro-2-chloroalkylpyrimidines (IIIa-n) have exhibited much superior antihyperlipidemic activity, compared to their earlier reported 4-hydroxy analogs. Notably, in this series, five compounds, IIIa, IIIb, IIIc, IIIi and IIIm showed good ability to reduce total cholesterol and two compounds, Ilia and IIIk exhibited better reduction in serum triglycerides. All the newly synthesized compounds have been evaluated by the Triton WR 1339 induced hyperlipidemia in albino Wistar rats model for antihyperlipidemic activity, and their activity is superior to that exhibited by the standard gemfibrozil used in the study. A 3D QSAR study has also been performed to delineate the effect of the substituents at 5 and 6 positions on the antihyperlipidemic activity of 2-chloromethyl-5,6-substituted thieno(2,34 pyrimidin-4(3H) -ones (IIa-e).
引用
收藏
页码:599 / 606
页数:8
相关论文
共 19 条
[1]  
*AM HEART ASS, 2003, HEART DIS STROK STAT
[2]   Ezetimibe [J].
Bays, H .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (11) :1587-1604
[3]   New advances in lipid-modifying therapies for reducing cardiovascular risk [J].
Bruckert, E .
CARDIOLOGY, 2002, 97 (02) :59-66
[4]   Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity [J].
Chrysselis, MC ;
Rekka, EA ;
Kourounakis, PN .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (04) :609-612
[5]   2-azetidinone cholesterol absorption inhibitors: Structure-activity relationships on the heterocyclic nucleus [J].
Clader, JW ;
Burnett, DA ;
Caplen, MA ;
Domalski, MS ;
Dugar, S ;
Vaccaro, W ;
Sher, R ;
Browne, ME ;
Zhao, HR ;
Burrier, RE ;
Salisbury, B ;
Davis, HR .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (19) :3684-3693
[6]   MECHANISM UNDERLYING HYPERCHOLESTEREMIA INDUCED BY TRITON WR-1339 [J].
FRIEDMAN, M ;
BYERS, SO .
AMERICAN JOURNAL OF PHYSIOLOGY, 1957, 190 (03) :439-445
[7]  
GEORGE T, 1971, INDIAN J CHEM, V9, P755
[8]   2-AMINO-THIOPHENE AUS METHYLENAKTIVEN NITRILEN CARBONYLVERBINDUNGEN UND SCHWEFEL [J].
GEWALD, K ;
SCHINKE, E ;
BOTTCHER, H .
CHEMISCHE BERICHTE-RECUEIL, 1966, 99 (01) :94-&
[9]  
GEWALD K, 1966, CHEM ABSTR, V64, P8118
[10]  
Libby Peter, 1998, American Journal of Medicine, V104, p14S, DOI 10.1016/S0002-9343(98)00041-2